Policy

Daniel Kelly, European Cancer Summit 2021: Eliminating HPV Cancers

Published Online: November 15th 2021

We were delighted to catch up with Prof Daniel Kelly (Cardiff University, Wales, UK) to discuss the latest policy developments in the mission of HPV cancer elimination and the gender neutral vaccination plan.

Questions
1. How are the World Health Organisation and Europe’s Beating Cancer Plan working together to tackle HPV-associated cancers? (00:20-01:18)
2. What has been the impact of the HPV vaccine in terms of cancer prevention? (01:18-02:28)
3. What are the hopes for gender neutral vaccination? (02:28-03:38)
4. Could you tell us a little about the European Cancer Organisation’s HPV Action Network and its aims? (03:38-04:43)
5. How is the HPV Action Network working to improve gender neutral vaccination availability across Europe? (04:43-05:47)

Speaker Disclosure: Daniel Kelly has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the European Cancer Summit 2021

Share this Video
Related Videos In Policy
Policy
Developed by Touch
Mark Lawler, European Cancer Summit 2022: The ECO-ASCO Special Network
Watch Time: 2 mins

The impact of the Russian invasion on Ukraine and how this has impacted clinical trials and cancer care in Europe. The Special Network on the Impact of the War in Ukraine on Cancer was established by ECO Board and ASCO soon after the war started, and now has representatives of over 300 organisations. In this […]

Policy
Developed by Touch
Mark Lawler, European Cancer Summit, 2022: What is the European Cancer Pulse?
Watch Time: 2 mins

Professor Mark Lawler (Queen’s University Belfast) summarizes the European Cancer Pulse, an exciting new tool that brings together data from 34 European countries and helps determine cancer care disparities on cancer burden, research spending, prevention efforts, early detection, diagnosis and treatment access, survivorship, impact of social determinants and much more. For more information, click here. […]

Policy
Developed by Touch
Mark Lawler, European Cancer Summit 2022: The European Groundshot
Watch Time: 2 mins

The European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission is a unique imitative launched this year aims to identify the challenges in cancer care in Europe. The COVID-19 pandemic has had a significant impact on cancer diagnosis and halted many ongoing clinical trials. In this video, Professor Mark Lawler (Queen’s University Belfast) describes […]

Trending In Policy:

Mark Lawler, European Cancer Summit 2022: The ECO-ASCO Special Network
Policy
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72